Passionate pharma executive with >25 years of experience in drug discovery and development. Proven ability to deliver pipeline value and products as evidenced by leadership of teams that developed the BACE inhibitor verubecestat (Ph 3, Alzheimer’s disease), the marketed NK1 antagonist rolapitant (VarubiTM, chemotherapy-induced nausea and vomiting), and the A2A antagonist preladenant (Ph 2/3, Parkinson’s disease, cancer). Strong skills and experience in:
Neuroscience, metabolic disease and oncology therapeutic areas
Leading and motivating diverse discovery and early development teams
Scientific strategy and vision
Translational science, including PK/PD, biomarker plans, modeling and simulation
Regulatory documentation and interactions
Collaborating with universities, CROs and pre-competitive consortia
Business development activities
Organizing and leading advisory board, investigator and KOL meetings